Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152463 | 0.85 | IGF1R (0.64) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL14465230 | 0.85 | IGF1R (0.57) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL2935837 | 0.84 | IGF1R (0.63) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL2939949 | 0.84 | IGF1R (0.86) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL1878651 | 0.84 | IGF1R (0.59) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL31330458 | 0.84 | IGF1R (0.71) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL1879763 | 0.84 | IGF1R (0.71) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL1879790 | 0.84 | IGF1R (0.71) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL4611034 | 0.84 | IGF1R (0.58) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL5188635 | 0.84 | IGF1R (0.49) | IGF1RPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1773809-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010643-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | PRKAR2B, PRKG2, PRKG1 | IGF1R 878/4885PPARG 4051/4885PPARD 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.